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Studies using PPARγ agonists in mouse skin have suggested that peroxisome proliferator-activated receptor gamma (PPARγ)i s
irrelevant to cutaneous photobiology. However, in several epithelial cell lines, ultraviolet B (UVB) has been shown to induce the
nonenzymatic production of oxidized phospholipids that act as PPARγ agonists. UVB is also a potent inducer of prostaglandin
E2 (PGE2) production and COX-2 expression in keratinocytes and PPARγ is coupled to increased PGE2 production in other cell
lines.Inthiscurrentstudy,wedemonstratethatPPARγagonists,butnotPPARαorPPARβ/δ agonists,inducePGE2 productionand
COX-2 expression in primary human keratinocytes (PHKs). Importantly, PPARγ agonist-induced COX-2 expression and PGE2
production were partially inhibited by the PPARγ antagonist, GW9662, indicating that both PPARγ-dependent and -independent
pathways are likely involved. GW9662 also suppressed UVB and tert-butylhydroperoxide- (TBH-) induced PGE2 production in
PHKs and intact human epidermis and partially inhibited UVB-induced COX-2 expression in PHKs. These ﬁndings provide
evidence that PPARγ is relevant to cutaneous photobiology in human epidermis.
1.Introduction
Peroxisome proliferator-activated receptors (PPARs) are
ligand-activated nuclear transcription factors that were ini-
tially identiﬁed as being crucial for regulating the formation
of intracellular organelles, called peroxisomes, that are
involved in lipid metabolism (reviewed in [1]). Three diﬀer-
ent PPARs subtypes have been cloned (α, β/δ,a n dγ) that
diﬀer in ligand speciﬁcity, tissue expression, and transcrip-
tional targets. All three PPARs require heterodimerization
with the retinoid X receptors (RXRs) for transcriptional
activity. PPAR:RXR heterodimers induce target gene tran-
scription by binding to speciﬁc peroxisome proliferators
response elements (PPREs) in the promoter region of target
genes [1]. Importantly, PPARα,P P A R β/δ,a n dP P A R γ are
all expressed in keratinocytes and in human and rodent
epidermis [1–3]. We have recently demonstrated that PPARγ
is expressed in adult primary human keratinocytes and three
diﬀerentimmortalizedormalignanthumankeratinocytecell
lines (A431, HaCaT, and KB cells) [4, 5]. In KB epidermoid
carcinoma cells and SZ95 sebocytes cells, we have also
demonstrated that oxidative stress, including ultraviolet B
irradiation,resultsintheproductionofoxidizedlipidspecies
with potent PPARγ ligand activity [4, 5].
Natural PPARγ ligands include metabolites of both the
cyclooxygenase(COX)andlipoxygenasepathways,including
thecyclopentanoneprostaglandin,15-deoxy-Δ12,14-prostagl-
andin J2, and 13-hydroxyoctadecadienoic acid (13-HODE)2 PPAR Research
(reviewed in [2]). However, these compounds are relatively
low-aﬃnity ligands that also exhibit PPARγ-independent
functions [6]. The most potent natural ligands for PPARγ
have been shown to be oxidized alkyl phospholipids. This
includes 1-hexadecyl 2-azelaoyl phosphatidylcholine (azPC),
a nonenzymatically oxidized alkyl glycerophosphocholine
ﬁrstdiscoveredassociatedwithoxidizedlow-densitylipopro-
tein [7]. Importantly, azPC has been shown to be produced
following UVB irradiation [4]. In addition, the thiazo-
lidinedione (TZD) compounds, troglitazone, ciglitazone,
rosiglitazone, and pioglitazone, are synthetic PPARγ agonists
that are widely used in the treatment of type II diabetes.
However, synthetic TZD PPARγ agonists have also been
shown to exhibit PPARγ-independent eﬀects [8–10]. This
underscores the importance of using appropriate controls,
such as the PPARγ-selective antagonist, GW9662, to verify
PPARγ-speciﬁc results when using these agonists [11].
While it is clear that UVB and other oxidative stressors
can result in PPARγ l i g a n dp r o d u c t i o n ,ap r e v i o u ss t u d y
using exogenous PPARγ agonists failed to demonstrate any
eﬀect on either chemical carcinogenesis or UVB-induced
skin cancer formation [12]. These negative ﬁndings raise
doubts concerning the relevance of PPARγ to cutaneous
photobiology. Yet, it should be noted that mice with
heterozygous germline deletion of PPARγ or mice with
epidermal-speciﬁc loss of PPARγ exhibit an increase in
chemical carcinogen-induced skin tumors [13, 14]. This
suggests the possibility that loss of function models, such
as the use of PPARγ antagonists rather than agonists, might
be more informative for studies designed to examine the
role of PPARγ in photobiology. Given that we have already
demonstrated that UVB induces PPARγ ligand formation,
we hypothesized that the lack of eﬀect of exogenous PPARγ
ligands on photocarcinogenesis could be explained by the
fact that PPARγ is already engaged by UVB-induced ligand
production. Inasmuch as our previous studies using cell
lines indicate that PPARγ is coupled to epithelial COX-2
expression and PGE2 production, we therefore utilized the
PPARγ antagonist, GW9662, to determine whether PPARγ
is involved in regulating UVB-induced COX-2 expression
and PGE2 production in primary human keratinocytes
and intact human epidermal explants. The results of the
present studies indicate that PPARγ is functionally coupled
to a readily measured photobiological response in human
primary epidermal keratinocytes and is therefore relevant to
cutaneous photobiology.
2.MaterialsandMethods
2.1. Materials. Ciglitazone, GW501516, and WY-14,643
were obtained from Alexis Biochemicals (San Diego,
CA). AzPC (1-O-Hexadecyl-2-Azelaoyl-sn-Glycero-3-Phos-
phocholine) was purchased from Avanti Polar Lipids
(Alabaster, AL). The speciﬁc PPARγ antagonist, GW9662,
was obtained from Cayman Chemical (Ann Arbor, MI). The
selective COX-2 inhibitor, NS398, was obtained from Sigma-
Aldrich (St. Louis, MO). All other reagents were obtained
from Sigma-Aldrich unless otherwise noted.
2.2. Cell Culture. Adult primary human keratinocytes
(PHKs) were prepared from discarded epidermis that
was obtained from reductive mammoplasties and pan-
niculectomies as previously described [15]. Telomerase-
immortalized primary human keratinocytes (N/TERT-1)
wereobtainedfromDr.Rheinwald(DepartmentofMedicine
and Harvard Skin Disease Research Center, Brigham, and
Women’s Hospital, Boston, MA) [16]. PHKs and N/TERT-
1 cells were cultured on tissue culture plastic or wells that
were precoated with type I collagen. PHKs and N/TERT-1
cells were grown in serum-free media (Keratinocyte serum-
free media, K-SFM; Gibco Invitrogen, Carlsbad, CA). Media
were supplemented with 40IU per mL penicillin, 40μgp e r
mL streptomycin, and 0.1μg per mL amphotericin B. The
cells were cultured in 95% air and 5% CO2 at 37
◦C. All
studies were done using PHKs or N/TERT-1 cells that were
plated at suﬃcient density to achieve approximately 70%–
80% conﬂuence prior to experimental manipulation. All
studies with human skin have been approved by the Indiana
University-Purdue University at Indianapolis Institutional
Review Boards using the Declaration of Helsinki Principles.
2.3. Immunoblotting. Immunoblotting for PPARγ was done
using mouse monoclonal anti-PPARγ antibody (clone E8;
Santa Cruz Biotechnology, Santa Cruz, CA), essentially as
described in [4]. The speciﬁcity of this antibody for PPARγ
has previously been demonstrated in wild-type versus tissue-
speciﬁc PPARγ knockout mice [17].
2.4. Ultraviolet B Irradiation of Cultured Keratinocytes. For
UVB irradiation studies, a Philips F20T12/UV-B lamp (270–
390nm), containing 2.6% UVC, 43.6% UVB, and 53.8%
UVA, was utilized. The UVB dose was measured using an
IL1700 radiometer and a SED240 UVB detector (Inter-
national Light, Newburyport, MA). All irradiations were
performed at a distance of 8cm from the UVB light source.
All irradiations were done on PHKs grown in 24-well plates.
For GW9662- and NS398-treated cells, media containing
vehicle, 1μM GW9662, or 10μM NS398 were added either
1 hour (GW9662) or 30 minutes (NS398) prior to UVB
irradiation. The cells were then washed twice with PBS, and
then the cells were irradiated with 600J/m2 UVB. DMEM
containing 10% FBS was then added containing vehicle,
GW9662, or NS398. After eight hours at 37◦C, the culture
supernatants were removed for PGE2 quantitation, the cell
monolayerwastrypsinized, andthecellswerecounted.PGE2
was then normalized to cell count.
2.5. Tert-Butylhydroperoxide (TBH) Studies in PHKs In Vitro.
For TBH studies, cells were plated onto 24-well plates in
high-calcium DMEM containing 10% fetal bovine serum.
The cells were then pretreated with GW9662 or NS398 as
detailed in the previous section prior to TBH addition.
Culture supernatants were then collected after an eight-hour
incubation at 37◦C.
2.6. PPAR Agonist Studies. For PPAR agonist studies, ago-
nists were added in low-calcium K-SFM media or in K-SFMPPAR Research 3
media supplemented with 1mM calcium and incubated for
24 hours at 37◦C. To assess PPARγ-dependent induction of
PGE2, GW9662 (1μM) was added 1 hour prior to agonist
addition. PGE2 was then quantitated in tissue culture media
by EIA and normalized to either cell count or total cellular
protein (BCA assay; Pierce Biotechnology, Rockford, IL).
2.7. RNA Isolation and COX-2 Quantitative RT-PCR. PHKs
were treated with vehicle and ciglitazone (with and without
GW9662) as detailed in the previous section. At 2, 4, 8, and
24 hours after the addition of reagents, the cell monolayers
were processed for RNA isolation using an RNeasy kit (Qia-
gen) according to the manufacturer’s protocol. Following
ﬁrst-strandDNAsynthesis,quantitativeRT-PCR(qRT-PCR)
was performed using primers speciﬁc to human COX-2
and 18S rRNA with a Cepheid Smart Cycler real-time PCR
instrument (Fisher Scientiﬁc, Pittsburgh, PA). COX-2 and
18S qRT-PCR were performed as previously described [5].
COX-2 results were then normalized to 18S using the ΔΔCt
method [18].
2.8. Human Epidermal Explant Preparation and UVB Irradi-
ation. Adult human epidermis obtained from panniculec-
tomies was obtained postoperatively. Subdermal fat and a
portion of the lower dermis were immediately removed
using a scalpel blade. The epidermis was then cut into small
(approx. 8 × 8mm) sections, weighed, and then cultured
in 12-well plates submerged in Keratinocyte-SFM media for
48–72 hours. The explants were then pretreated with vehicle,
1μM GW9662 (1 hour), or 10μM NS398 (30 minutes)
prior to UV treatment. After pretreatment, the explants were
washed twice with PBS and a minimal amount of PBS was
added to cover the explants to maintain hydration. The
explants were then irradiated with 1,800J/m2 of UVB light.
Control cells received no UVB light. The explants were then
submerged in serum-free DMEM containing vehicle, 1μM
GW9662, or 10μM NS398 and cultured for 8 hours at 37◦C.
At this time the media were removed for PGE2 quantitation.
All PGE2 levels were then normalized to tissue weight.
2.9. COX-2 Immunoblot. Second-passage PHKs grown on
6-well plates to near conﬂuence were treated with 1μM
GW9662 or vehicle 1 hour prior to washing the wells with
HBSS, then irradiating the cells with 300J/m2 of UVB.
The HBSS was then replaced with media containing vehicle
or 1μM GW9662, and the cells were processed 20 hours
later in RIPA buﬀer supplemented 1:100 with a protease
inhibitor cocktail (Sigma-Aldrich). Protein was quantitated
using a DC protein assay, and equal amounts of total protein
(50μg/lane) were then separated on 7.5% SDS-PAGE gels.
Rabbit polyclonal anti-COX-2 (Cayman Chemical) diluted
1:1000 in TBS with 0.1% Tween 20 and 2% Blotto was
added and incubated overnight at 4◦C in 2% Blotto. Goat
anti-rabbit HRP conjugate (1:10,000; Source) in 5% Blotto
was applied and the immunoreactive bands were detected
enhancedchemiluminescence.Theexposedﬁlmsweredevel-
oped and scanned and band intensity was determined using
NIH Image J software. The band intensity of the COX-2
Ind I Ind II N/TERT-1
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Figure 1:PPARγ expressionbyimmunoblotinPHKs.40μgcellular
protein isolated from PHKs from two diﬀerent individuals was
grown on tissue culture plastic coated with (Coll) and without
(Plas)typeIrattailcollagen.Proteinfromtelomerase-immortalized
primary human keratinocytes (N/TERT-1) was also utilized. In all
cases, the proteins were separated on a 10% SDS-PAGE and PPARγ
protein was detected using a monoclonal anti-PPARγ antibody.
Loading was veriﬁed by stripping the blots and performing an
immunoblot for β-Actin.
band at 72kDa was normalized to that of an invariant non-
speciﬁchigh-molecular-weightband(>180kDa)observedin
all lanes.
2.10. PGE2 Quantitation. PGE2 was quantitated as previ-
ously described in culture media using a commercial PGE2
EIA kit (Cayman Chemical, Ann Arbor, MI) [4].
3. Results and Discussion
3.1. Primary Human Keratinocytes Express PPARγ. Studies in
mouse skin have shown that PPARγ is expressed at low levels
and may be functionally irrelevant in mouse keratinocytes
[8, 12]. We therefore ﬁrst veriﬁed that PPARγ is expressed
in the PHKs from several diﬀerent individuals under several
diﬀerent culture conditions (culture on plastic or type I
collagen) (Figure 1). To exclude the possibility that the
PPARγ seenintheseprimarycultureswasderivedfromother
cell types, immunoblotting for PPARγ was also done on
telomerase-immortalized human keratinocytes (N/TERT-1)
[16]. This data supports previous reports that PHKs express
mRNA and protein for PPARγ [19–21].
3.2. PPARγ Agonists, but not PPARα and PPARβ/δ Agonists,
Stimulate PGE2 Formation in PHKs through Both PPARγ-
Dependent and -Independent Mechanisms. In SZ95 sebo-
cytes, we have previously demonstrated that GW9662 was
eﬀective in blocking PGE2 production elicited by the syn-
thetic PPARγ agonist ciglitazone [5]. We therefore examined
whether ciglitazone could also induce PGE2 formation in
P H K s .G i v e nt h a taT Z Dt y p eo fP P A R γ agonist has been
reported to induce COX-2 expression independent of PPARγ
in a mouse keratinocyte cell line [22], we also examined
whether the endogenous PPARγ ligand, azPC, could also
induce PGE2 production in PHKs. Finally, the ability of
PPARα or PPARβ/δ to regulate PGE2 production in PHKs
was also examined. In Figure 2(a), we demonstrate that
treatment of PHKs with the PPARγ agonists, ciglitazone, and4 PPAR Research
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Figure 2: PPARγ agonists, but not PPARα or β/δ agonists, induce PGE2 production in PHKs; PPARγ agonist-induced PGE2 production
and COX-2 mRNA expression are inhibited by GW9662. (a) PPARγ agonists, but not PPARα or β/δ agonists, induce PGE2 production in
PHKs. PHKs were treated for 24 hours with vehicle (CONT), 5μMo ft h eP P A R γ agonist, ciglitazone (CIG), 1μM of the endogenous PPARγ
agonist, azPC, a PPARα agonist (WY-14,643, 1μM), or a PPARβ/δ agonist (GW501516, 500nM). The media were then removed and PGE2
was quantitated in the culture media using a commercial PGE2 EIA kit. Values represent the mean ± SEM of PGE2 levels as a percent of
control levels (N = 5 experiments done in triplicate).
∗P <. 05, one sample t-test. (b) GW9662 inhibits PPARγ agonist-induced PGE2
production in PHKs but has no signiﬁcant eﬀect on vehicle-treated cells. PHKs were pretreated for 1 hour with 1μM GW9662 prior to
addition of vehicle (VEH), ciglitazone (5μM), or azPC (1μM) for 24 hours. PGE2 was then quantitated in tissue culture supernatants. The
results shown represent the percent inhibition of vehicle or agonist-induced PGE2 formation by GW9662. Mean and SEM.
∗∗P <. 01, one-
samplet-test.(c)GW9662treatmentinhibitsciglitazone-inducedCOX-2mRNAexpression.PHKsweretreatedwithvehicleandciglitazone,
with and without GW9662, as detailed in Figure 2(b) above. At 2, 4, 8, and 24 hours, total RNA was isolated and quantitative RT-PCR was
performed for COX-2 mRNA and 18S rRNA expression. The results are shown as COX-2 expression normalized to 18S and expressed as a
fold change relative to VEH control (assigned a value of 1 for all time points). When data for all time points was analyzed, only ciglitazone-
treated cells exhibited a signiﬁcant induction in COX-2 expression (one-sample t-test, P = .0101).
azPC results in a signiﬁcant increase in PGE2 production.
The PPARα agonist, WY-14,643, resulted in only a slight,
but reproducible, increase in PGE2 production. Treatment
with a PPARβ/δ agonist (GW501516, 500nM) did not alter
PGE2 production.ItshouldbenotedthatNS398signiﬁcantly
blocked both basal and PPARγ agonist-induced changes in
PGE2 production. As a percent of the vehicle control-treated
cells, PGE2 levels were 8.1 ± 7.4% (n = 4), 11.2 ± 12.5%
(n = 4), and 12.2 ± 8.8% (n = 3) for NS398 treatment
alone, ciglitazone + NS398, and azPC + NS398-treated cells,
respectively.
The above studies suggest that PPARγ,b u tn o tP P A R α
or PPARβ/δ,i sc o u p l e dt oP G E 2 production in PHKs. To
determine whether ciglitazone- and azPC-dependent PGE2
production was speciﬁc to PPARγ, we next examined the
ability of GW9662 to block PPARγ agonist-induced PGE2
production. As shown in Figure 2(b), pretreatment of PHKs
with 1μM GW9662 resulted in a signiﬁcant inhibition of
bothciglitazone-andazPC-inducedPGE2 production.How-
ever, this inhibition was not complete: GW9662 inhibited
ciglitazone-andazPC-inducedPGE2 productionby59%and
62%, respectively. In contrast, GW9662 had no signiﬁcant
eﬀectonvehicle-treatedkeratinocytes.Inasmuchasthissame
dose of GW9662 completely inhibited ciglitazone-induced
PGE2 f o r m a t i o ni nS Z 9 5s e b o c y t e s[ 5], this data suggests
that PGE2 production induced by azPC and ciglitazonePPAR Research 5
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Figure 3: The speciﬁc PPARγ antagonist GW9662 blocks UVB- and TBH-induced PGE2 production and UVB-induced COX-2 protein
expression. (a) GW9662 inhibits UVB- and TBH-induced PGE2 production in PHKs. PHKs were pretreated with vehicle control (VEH),
GW9662 (1μM)for1hour,ortheCOX-2inhibitorNS398 (10μM)for30minutes, thentreated with 10μMtert-butylhydroperoxide (TBH),
500nM calcium ionophore A23187, or exposed to 600J/m2 UVB irradiation (UV), respectively. PGE2 production was assayed in the tissue
culture supernatants after 8 hours and was normalized to tissue weight. The values of PGE2 expression shown are mean ± SEM and are
representative of three experiments (∗P<. 05,
∗∗P <. 01,
∗∗∗P <. 001 by t-test compared with nonirradiated vehicle control †,o r
from the respective UV- or TBH-treated cells without GW9662 pretreatment §). (b) GW9662 inhibits UVB-induced COX-2 expression
by immunoblot. PHKs were pretreated with vehicle (VEH) or 1μM GW9662 (GW) 1 hour prior to irradiation with 300J/m2 UVB (UV).
After 20 hours, total cellular protein was isolated and immunoblots were performed for COX-2 expression (a) as detailed in the methods
section. (b) shows a high MW nonspeciﬁc invariant band used to normalize for COX-2 expression. After ﬁlm exposure, band intensities
were assessed using NIH Image J. Normalized band intensities are shown at the bottom as a relative increase from VEH control cells.
occurs through both PPARγ-dependent and -independent
mechanisms in PHKs.
As noted above, the ability of NS398 to inhibit basal
and PPARγ agonist-induced PGE2 production suggests that
PPARγ agonists induce expression of COX-2. We have previ-
ouslydemonstratedthat PPARγ is coupledtoUVB-and tert-
butylhydroperoxide-mediated COX-2 expression in SZ95
sebocytes.ThisideaissupportedbystudiesinSZ95sebocytes
in which the PPARγ antagonist GW9662 completely blocks
PGE2 formation induced by ciglitazone, UVB, and TBH [5].
Moreover, the COX-2 promoter is known to contain putative
peroxisome proliferators response elements (PPREs) [23].
Thus, we next examined the ability of ciglitazone to induce
COX-2 expression in PHKs. In Figure 2(c), we show that
COX-2 mRNA expression is induced from 2 to 24 hours
after ciglitizone addition. Moreover, GW9662 treatment
suppressed COX-2 induction.
3.3. PPARγ Mediates UVB and Oxidative Stressor-Induced
PGE2 Production. We have previously demonstrated that
UVB exposure activates PPARγ via the production of
oxidized lipid species in KB epidermal carcinoma cells
and SZ95 sebocytes [4, 5]. Moreover, UVB-induced PPARγ
activation is necessary for optimal UVB-mediated COX-
2 expression or PGE2 production in both KB cells and
SZ95 sebocytes [4, 5]. Finally, the lipid soluble oxidant,
TBH, also induces COX-2 and PGE2 production in SZ95
sebocytes through a PPARγ-dependent mechanism [5]. We
therefore sought to establish the importance of PPARγ in
photobiology by demonstrating that PPARγ antagonism
could alter UVB-mediated induction of PGE2 production in
PHKs. As shown in Figure 3, both UVB and the lipid soluble
oxidant TBH were capable of inducing a marked increase
in PGE2 production in PHKs. Importantly, pretreatment
with the PPARγ-speciﬁc antagonist, GW9662, blocked 68%
of the TBH and 80% of the UVB-mediated increases in
PGE2. The ability of the selective COX-2 inhibitor, NS398,
to inhibit PGE2 formation was utilized as a negative control.
As expected, NS398 markedly suppressed basal and UVB-
induced PGE2 production. The calcium ionophore, A23187,
which is a potent activator of both COX-2 and upstream
phospholipases, was utilized as an irrelevant positive control.
As expected, GW9662 had no aﬀect on ionophore-induced
PGE2.
Finally, we examined the ability of GW9662 to inhibit
UVB-induced COX-2 expression. In Figure 3(b), we show
a representative immunoblot demonstrating that GW9662
strongly inhibits UVB-induced COX-2 expression (mean
suppression of 61.5% in two separate experiments).
3.4. UVB-Induced PGE2 Production Occurs via PPARγ in
Human Epidermal Explants. The above studies indicate that
PPARγ antagonism suppresses UVB- and TBH-induced
PGE2 production and COX-2 expression in cultured PHKs
in vitro. We next sought to determine whether PPARγ
antagonism could alter UVB-induced PGE2 formation in
intact human skin ex vivo. In Figure 4(a), we show that
skin explants exposed to 1,800J/m2 of UVB exhibited
a signiﬁcant increase in PGE2 production at 8 hours.
Importantly, UVB-induced PGE2 production was nearly
completely blocked by pretreatment with 1μM GW9662.
A similar induction of PGE2 production was observed
24 hours after UVB irradiation, which was also blocked
by pretreatment with GW9662 (Figure 4(b)). Finally, as
a negative control, we show that the COX-2 inhibitor,
NS398, suppresses both control and irradiated PGE2 levels.6 PPAR Research
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Figure 4:PPARγ activationisapotentinducerofPGE2 productioninhumanepidermalexplants.Humanepidermalexplantswereprepared
as described in the methods section and placed into K-SFM media (Invitrogen). Prior to UVB (UV) irradiation, the explants were pretreated
with 1μM GW9662 for 1 hour or 10μM NS398 for 30 minutes. The explants were then washed once in PBS and irradiated with 1800J/m2
UVB. Media containing vehicle (CONT), 1μM GW9662, or 10μM NS398 were then added back and the explants were cultured for 8 hours
(a) or 24 hours (b). Tissue culture supernatants were then removed for PGE2 quantitation by EIA. PGE2 results were normalized to tissue
weight. Results are presented as a percent change from control PGE2 levels. Mean and SEM of 2–4 experiments were done in triplicate.
(∗P<. 05, one-sample t-test compared with nonirradiated vehicle control †, or from UV-treated skin without GW9662 pretreatment §).
These studies show that GW9662 is eﬀective topically and
also veriﬁes the importance of PPARγ in mediating a
photobiological response in intact human skin.
4. Conclusions
Inasmuch as the epidermis is constantly exposed to ultravi-
olet light and other oxidative stressors, it is not surprising
that epidermal cells would have developed intracellular
mechanisms to detect and respond to these stresses. Among
the many cellular signaling pathways that are induced by UV
light, COX-2 induction and PGE2 production have been well
described [5, 23, 24]. We have recently demonstrated that
UVBinducesPGE2 synthesisviatheproductionofoxidative-
stress-induced PPARγ-speciﬁc ligands in other cell types [4,
5]. Thus, PPARγ may serve as a cellular “signal transducer”
that converts oxidative stress into cellular responses. In this
study, we demonstrate that PPARγ agonists, including cigli-
tazone and azPC, are capable of inducing PGE2 production
in cultured PHKs. We then demonstrate that UVB- and
TBH-induced PGE2 production in human epidermis ex vivo
and cultured PHKs in vitro occurs via a PPARγ-dependent
mechanism. The role of COX-2 in PGE2 production in
PHKs was veriﬁed by demonstrating that GW9662 inhibits
ciglitazone-induced COX-2 mRNA expression as well as
UVB-induced COX-2 protein expression. Collectively, these
ﬁndings strongly suggest that PPARγ acts as a photosensor
(and likely an oxidative stress sensor) that acts to translate
the insult into a biochemical signaling cascade.
Previous work has generated conﬂicting data regard-
ing the functional relevance of PPARγ in epidermal and
keratinocyte biology. In mice, one group failed to observe
PPARγ expression in cultured SKH-1 hairless mouse ker-
atinocytes by RT-PCR [8]. In yet another study, PPARγ
was observed to be expressed at the mRNA level in human
primary keratinocytes, yet functional PPARγ activity was
not observed using a PPRE-luciferase reporter assay [19].
However, another group demonstrated that PPARγ was
expressedinkeratinocytesisolatedfromSENCARmiceusing
immunoblot analysis [25]. Yet another study using PPARγ
conditional knockout mice demonstrated that PPARγ is
involved in epidermal diﬀerentiation [26]. In our studies,
we demonstrate that PPARγ is expressed at the protein
level in primary human keratinocytes and that PPARγ is
coupled to UVB- and TBH-induced PGE2 production. Our
ﬁndings that PPARγ mediates UVB- and TBH-induced
PGE2 production provide additional evidence that PPARγ
is functionally relevant to human cutaneous biology and, in
particular, is relevant to human keratinocyte photobiology.
This is particularly important given previous work by our
group and others demonstrating that endogenous PPARγ
ligand formation is induced by oxidative stress, including
UVB [4, 5, 27, 28].
While our studies indicate a clear role for PPARγ
in regulating UVB- and TBH-induced PGE2 production
in PHKs, previous studies have shown that PPARα and
PPARβ/δ are also expressed in human epidermis and cul-
turedkeratinocytes[1,20].ThoughaPPARαagonistinduced
a small amount of PGE2 formation in PHKs (Figure 2(a)),
our data does not support a role for either PPARα or
PPARβ/δ as major mediators of increased PGE2 production
in PHKs.
Recent studies have demonstrated that mice with hem-
izygous germline loss of PPARγ and epidermal-speciﬁc loss
ofPPARγ exhibitincreasedsusceptibilitytocutaneouschem-
ical carcinogenesis [13, 14]. This data indicates a possible
role for PPARγ as a tumor-suppressing agent in skin. Studies
are currently underway to examine the potential role of
PPARγ in cutaneous photocarcinogenesis. It should be noted
that recent studies by He et al. (2005) indicate that topicalPPAR Research 7
or systemic administration of TZD-type PPARγ agonists
have no signiﬁcant eﬀect on chemical (DMBA/phorbol
ester) or UVB-mediated carcinogenesis [12]. There could
be several explanations for this discrepancy. First, we and
others have previously shown that UVB or other oxidative
stressors induce PPARγ ligand production from cellular
glycerophosphocholines [4, 7]. Moreover, phorbol esters
act to induce oxidative stress, including the production of
oxidizedlipidsinepidermis[29,30].Thus,itisquitepossible
that PPARγ receptors are already engaged by endogenous
PPARγ ligands produced through phospholipid oxidation,
thus mitigating the eﬀects of exogenous ligand. Alternatively,
a followup study by He et al. (2006) indicated that TZD-type
PPARγ agonists induce COX-2 expression in a keratinocyte
cell line lacking PPARγ [22]. The authors speculate that this
PPARγ-independent production of protumorigenic COX-2
may counteract any tumor-suppressing function of PPARγ.
This PPARγ-independent induction of COX-2 would also
explain the results seen in Figures 2 and 3, in which GW9662
was unable to completely abolish PPARγ agonist or UVB-
induced PGE2 production and COX-2 expression. Finally,
thediﬀerencescouldpotentiallybeexplainedbyvariationsin
the murine genetic background or carcinogenesis protocol.
In addition to a potential role for PPARγ in cutaneous
photocarcinogenesis, independent lines of evidence suggest
thatPPARγ shouldbeafocusforfuturestudiesexaminingits
potential role as a mediator of phototherapeutic responses.
Recently, PPARγ agonists have been shown to be eﬀective
antipsoriatic agents by reducing the keratinocyte hyperplasia
associated with psoriasis [31]. This is signiﬁcant as UVB
exposure is a well-known treatment option for patients with
psoriasis. Since psoriasis is thought to occur as a result
of deregulated T-cell function [32, 33], it is interesting
that both PPARγ [34–36]a n dP G E 2 [37–39]a c ta sT - c e l l
and dendritic cell immunosuppressants and that topical
application of PGE2 has been shown to result in clinical
improvement of psoriatic lesions [40]. Given our ﬁndings
that UVB activates keratinocyte PPARγ, it is possible that
some of the therapeutic beneﬁts of UVB treatment may be
due to PPARγ activation.
In conclusion, we provide evidence that PPARγ stimu-
lates PGE2 formation in PHKs. Moreover, PPARγ mediates
UVB- and TBH-induced PGE2 production in human epi-
dermis and primary human keratinocytes. This suggests that
PPARγ may play an important role in UVB- and oxidative-
stress-induced changes in epidermal biology.
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